Vivimed Labs Limited — Updates, 13-11-2025: General Updates

Vivimed Labs reported Q2 & H1 financial results with substantial losses. The board approved filing for a pre-packaged insolvency resolution process. Auditors issued a qualified opinion for unprovisioned interest expenses of **Rs 30.71 Cr** for the half-year, significantly impacting actual financials. Trading suspension is expected to be revoked.